Logo Lanfrica
  • Home
  • Atlas
  • Insights
  • Docs
  • Sign in

© 2026 Lanfrica. All rights reserved. All copyrights of the resources shown on the Lanfrica website belong to the original copyright holders, unless explicitly stated otherwise.

<p>Adverse Events experienced by participants.</p>

Domain:

healthcare

Record type:

dataset
Creator:
MonUteBetJen
Host:avatar

Background

Onchocerciasis, also known as river blindness, remains a public health challenge in tropical regions. Despite significant gains through mass drug administration (MDA) with ivermectin, the infection remains persistent in many endemic foci. While the disease burden has reduced, elimination may require alternative strategies, including macrofilaricidal therapies. Rifampicin (RIF) has demonstrated strong anti-Wolbachia activity in vitro and in animal models, but its clinical efficacy in humans remains uncertain.

Methods

We conducted a phase II randomized, controlled trial in Ghana to evaluate the safety and efficacy of high-dose RIF (35 mg/kg/day) combined with albendazole (ALB, 400 mg/day) as an alternative treatment for onchocerciasis. The study randomized 120 infected participants into one of four arms: RIF + ALB for 14 days (TA1), RIF + ALB for 7 days (TA2), ALB alone for 14 days (TA3), and a No Treatment control group (TA4). Treatment efficacy, including Wolbachia and microfilariae (MF) depletion, adult worm vitality and embryogenesis were assessed following treatment at 4-, 18-, and 20-months.

Results

High-dose RIF + ALB was safe and well-tolerated, associated with only mild, transient adverse events. Treatment with RIF + ALB for 14 days reduced Wolbachia load in skin MF at 4 months (47.9%; p = 0.018). ALB monotherapy showed sustained reductions in skin microfilarial densities at the 18- and 20-month time points (p < 0.05). However, no macrofilaricidal effect or sustained Wolbachia depletion in adult worms was observed in any group.

Conclusion

High-dose RIF + ALB is safe with limited macrofilaricidal efficacy in clinical settings, contrasting with the superiority observed from preclinical trials. ALB alone shows promise as an alternative microfilaricidal treatment to ivermectin or as a complementary regimen. The lack of sustained efficacy of RIF as an anti-Wolbachia regimen may reflect suboptimal dosing, highlighting the need for further optimization of RIF-based regimens for onchocerciasis treatment.

Trial registration

PACTR202009704006025 (https://pactr.samrc.ac.za/S…). Date of trial registration: September 9, 2020

Visit

figshare.com

Tags

MedicinePharmacologyBiotechnologyCancerInfectious DiseasesVirologytransient adverse eventspublic health challengephase ii randomizedmass drug administration+41

Licenses

CC BY 4.0

Similar

<p>Storybook by participants aged 15–19 years.</p><p>Storybook by participants aged 10–14 years.</p><p>Participants’ Background Data.</p><p>Experienced stigma scale items.</p><p>Adverse event assessment.</p><p>Description of the participants.</p>

<p>Storybook by participants aged 15–19 years.</p>

Background

In Eswatini, adolescents living with HIV (ALHIV) face disproportionate chal

<p>Storybook by participants aged 10–14 years.</p>

Background

In Eswatini, adolescents living with HIV (ALHIV) face disproportionate chal

<p>Participants’ Background Data.</p>

Background

In Ghana, traditional medicine practitioners (TMPs) are often the first po

<p>Experienced stigma scale items.</p>

Background

People with disabilities face stigma and discrimination which contribute to

<p>Adverse event assessment.</p>

Background

Onchocerciasis, also known as river blindness, remains a public health cha

<p>Description of the participants.</p>

Medical and nursing students widely use ChatGPT and other artificial intelligence (AI) for t